Apr 23, 2012 | Polina Voloshko, MD, and Joseph McPhillips, PhD

Major Cardiotoxicity Biomarkers During Oncology Development

Many patients who have benefited from effective chemotherapy now face increased risks of morbidity and mortality from acute and delayed toxic effects of chemotherapeutic agents.

Cardiotoxicity has become one of the most important complications of cancer chemotherapy, therefore, assessment of cardiac function should be part of every Phase I through Phase III clinical trial of anti-tumor agents in development.

Download our white paper to discover major cardiotoxicity biomarkers during oncology development, including: